Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $8.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 365.12% from the stock’s current price.

Several other analysts have also commented on GANX. Chardan Capital reiterated a “buy” rating and issued a $6.00 price target on shares of Gain Therapeutics in a research report on Friday, August 9th. Oppenheimer reissued an “outperform” rating and issued a $8.00 price target on shares of Gain Therapeutics in a research note on Wednesday, August 14th.

Gain Therapeutics Stock Performance

NASDAQ GANX opened at $1.72 on Monday. The business’s 50 day moving average is $2.06 and its two-hundred day moving average is $1.72. The stock has a market capitalization of $45.61 million, a price-to-earnings ratio of -1.56 and a beta of 0.33. Gain Therapeutics has a 12-month low of $0.89 and a 12-month high of $5.33. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04.

Institutional Trading of Gain Therapeutics

A number of institutional investors have recently modified their holdings of GANX. Warberg Asset Management LLC purchased a new stake in shares of Gain Therapeutics during the 2nd quarter worth about $66,000. Renaissance Technologies LLC boosted its holdings in Gain Therapeutics by 154.2% in the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after acquiring an additional 72,000 shares during the period. Hohimer Wealth Management LLC acquired a new position in shares of Gain Therapeutics in the 2nd quarter valued at approximately $422,000. Finally, Geode Capital Management LLC raised its position in shares of Gain Therapeutics by 48.0% in the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after purchasing an additional 88,236 shares in the last quarter. Hedge funds and other institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.